News - AbbVie, Antibiotics and Infectious diseases

Filter

Popular Filters

AbbVie presents positive Phase III results in patients with chronic hepatitis C

AbbVie presents positive Phase III results in patients with chronic hepatitis C

04-03-2014

The first detailed results from US drugmaker AbbVie’s pivotal Phase III study, PEARL-III, have been…

AbbVieAntibiotics and Infectious diseasesPharmaceuticalResearchUSA

AbbVie’s hepatitis C Phase III trials all record top results

AbbVie’s hepatitis C Phase III trials all record top results

04-02-2014

US drugmaker AbbVie has announced the completion of its Phase III clinical program and released results…

AbbVieAntibiotics and Infectious diseasesPharmaceuticalResearchUSA

AbbVie reports 96% response in Phase III hepatitis C study

AbbVie reports 96% response in Phase III hepatitis C study

10-12-2013

US drugmaker AbbVie (NYSE: ABBV)has released Phase III results for the investigational three direct-acting-antiviral…

AbbVieAnti-viralsAntibiotics and Infectious diseasesPharmaceuticalResearchUSA

AbbVie releases positive Phase III results for oral hepatitis C program

AbbVie releases positive Phase III results for oral hepatitis C program

18-11-2013

US drugmaker AbbVie has released the first Phase III results for the investigational three direct-acting-antiviral…

AbbVieAntibiotics and Infectious diseasesNorth AmericaPharmaceuticalResearchUSA

Rise in infections means hepatitis C market is expected to peak at $15.5 billion in 2022

27-08-2013

The hepatitis C market is forecast to increase by a massive 230% in the next nine years, according to…

AbbVieAntibiotics and Infectious diseasesBristol-Myers SquibbGilead SciencesGlobalJohnson & JohnsonMarkets & MarketingPharmaceuticalsofosbuvir

Back to top